Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Mirum Pharmaceuticals (NASDAQ: MIRM) recently:

• 5/19/2025 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
• 5/13/2025 – Mirum Pharmaceuticals had its “strong-buy” rating reaffirmed by analysts at Raymond James.
• 5/13/2025 – Mirum Pharmaceuticals had its price target raised by analysts at Raymond James from $73.00 to $77.00. They now have a “strong-buy” rating on the stock.
• 5/9/2025 – Mirum Pharmaceuticals had its price target raised by analysts at JMP Securities from $74.00 to $76.00. They now have a “market outperform” rating on the stock.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $44.31 on Thursday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -21.94 and a beta of 0.95. The firm has a 50-day simple moving average of $42.98 and a two-hundred day simple moving average of $44.55. Mirum Pharmaceuticals, Inc. has a one year low of $23.83 and a one year high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue was up 61.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.54) earnings per share. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. This trade represents a 16.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now owns 4,841 shares of the company’s stock, valued at $214,698.35. The trade was a 92.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,764 shares of company stock worth $4,109,161 over the last 90 days. 14.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MIRM. Nuveen LLC acquired a new position in Mirum Pharmaceuticals in the first quarter valued at approximately $29,495,000. Federated Hermes Inc. boosted its holdings in Mirum Pharmaceuticals by 9,440.4% during the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company’s stock worth $15,649,000 after buying an additional 343,725 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $10,611,000. Nuveen Asset Management LLC boosted its holdings in Mirum Pharmaceuticals by 46.7% during the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company’s stock worth $29,861,000 after buying an additional 229,746 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in Mirum Pharmaceuticals by 3.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 6,795,121 shares of the company’s stock worth $306,120,000 after buying an additional 224,729 shares in the last quarter.

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.